Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors

NCT ID: NCT06588569

Last Updated: 2024-09-19

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-12
• Study Completion Date: 2025-12-31

Brief Summary

This single-center, parallel-controlled clinical trial aims to establish a multi-mode ablation system for liver malignant tumors originating from the digestive system. The study will evaluate the safety and efficacy of multi-mode tumor ablation, utilizing a multi-mode imaging platform for ablation planning and immediate evaluation of intraoperative ablation effects. Additionally, the study will employ multi-omics and multi-mode imaging techniques to explore the spatiotemporal heterogeneity and immune escape mechanisms of liver metastases from gastrointestinal tumors, providing guidance for treatment strategy formulation and prognostic evaluation.

Detailed Description

This is a single-center, parallel-controlled clinical trial. The study includes a total enrollment of 20 subjects. 10 patients with primary liver cancer will be divided into an experimental group and a control group (5 cases per group); 10 patients with Colorectal Cancer Liver Metastases will also be divided into the experimental group and the control group (5 cases per group). The purpose is to validate the safety and efficacy of multi-mode tumor ablation for liver malignant tumors, aiming to establish a multi-mode tumor treatment system and obtain multi-dimensional biomedical information from patients before, during and after ablation.

The study will employ an interdisciplinary approach, integrating statistics, machine learning and artificial intelligence, to establish a new technical system for rapid efficacy evaluation. Additionally, it will establish a multi-omics artificial intelligence-assisted diagnostic and evaluation system based on radiomics. The system will use artificial intelligence algorithms to automatically locate and identify lesions based on imaging guidance information and accurately predict individual prognoses and anti-tumor immune states through comprehensive preoperative, intraoperative, and postoperative evaluations, providing an important basis for treatment planning, intraoperative dose adjustment, and subsequent treatment strategies.

Conditions

Primary Liver Cancer; Colorectal Cancer Liver Metastases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Multi-mode Ablation

This arm includes patients with primary liver cancer or colorectal cancer liver metastasis (five cases each, totaling ten cases) who will receive multi-mode ablation, a novel ablation therapy that combines cryoablation and radiofrequency ablation.

Group Type: EXPERIMENTAL

Multi-mode tumor treatment system

Intervention Type: DEVICE

The intervention for this arm involves the use of a novel multi-mode tumor treatment system, developed by Shanghai MAaGI Medical Technology Co., Ltd. The system combines cryoablation and radiofrequency ablation in a single device. During the treatment, the tumor tissue is rapidly frozen to create an ice ball larger than the lesion by 5mm, followed by thawing and rewarming. Subsequently, the lesion is treated with radiofrequency ablation according to conventional procedures to ensure complete ablation within a safety margin of 5-10mm around the tumor.

Conventional Radiofrequency Ablation

This arm includes patients with primary liver cancer or colorectal cancer liver metastasis (five cases each, totaling ten cases) who will receive conventional radiofrequency ablation treatment.

Group Type: ACTIVE_COMPARATOR

Radiofrequency ablation therapeutic apparatus

Intervention Type: DEVICE

The intervention for this arm involves the use of conventional radiofrequency ablation equipment, which is developed by MedSphere International (Shanghai) Co., Ltd.. During the treatment, the tumor is ablated using predefined power and time settings to ensure complete ablation within a safety margin of 5-10mm around the tumor.

Interventions

Multi-mode tumor treatment system

The intervention for this arm involves the use of a novel multi-mode tumor treatment system, developed by Shanghai MAaGI Medical Technology Co., Ltd. The system combines cryoablation and radiofrequency ablation in a single device. During the treatment, the tumor tissue is rapidly frozen to create an ice ball larger than the lesion by 5mm, followed by thawing and rewarming. Subsequently, the lesion is treated with radiofrequency ablation according to conventional procedures to ensure complete ablation within a safety margin of 5-10mm around the tumor.

Intervention Type: DEVICE

Radiofrequency ablation therapeutic apparatus

The intervention for this arm involves the use of conventional radiofrequency ablation equipment, which is developed by MedSphere International (Shanghai) Co., Ltd.. During the treatment, the tumor is ablated using predefined power and time settings to ensure complete ablation within a safety margin of 5-10mm around the tumor.

Intervention Type: DEVICE

Other Intervention Names

MTT-P1; S-1500

Eligibility Criteria

Inclusion Criteria

1. Age 18 and 75 years, gender not specified;

2. Pathologically confirmed primary liver cancer or colorectal cancer liver metastases, which is unresectable, intolerant to surgical resection, or refused surgical resection;

3. Intrahepatic lesions with a diameter of ≤4cm, and the number of lesions ≤3.;

4. At least 3 months since the last systemic treatment and at least 1 month since the last local treatment;

5. Child-Pugh class A or B;

6. ECOG PS ≤ 2.

Exclusion Criteria

1. Liver function Child-Pugh class C , severe jaundice, especially obstructive jaundice;

2. Diffuse liver cancer, or with tumor thrombi in the main portal vein to secondary branches or hepatic vein;

3. Significant liver atrophy, tumor volume too large, requiring ablation range of up to one-third of the liver volume;

4. Multiple systemic metastases, expected survival < 3 months;

5. Recent history of esophageal (gastric fundus) variceal bleeding within the past month;

6. Severe functional failure of major organs such as the liver, kidneys, heart, lungs or brain;

7. Presence of active infection;

8. Uncorrectable coagulation dysfunction and severe hematological abnormalities, with a significant bleeding tendency;

9. Refractory massive ascites, pleural effusion, or cachexia;

10. Pregnancy, disorder or inability to cooperate with treatment;

11. Any other factors deemed inappropriate for inclusion or affecting the subject's participation in the study, as determined by the investigators.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fudan University

OTHER

Sponsor Role: lead

Responsible Party

Wen-Tao Li

Director of Interventional Therapy Department

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Director of Interventional Therapy Department

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Fudan University Shanghai Cancer Center

Shanghai, , China

Countries

China

Other Identifiers

IR20210728

Identifier Type: -

Identifier Source: org_study_id